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base-case analysis. RESULTS: Base case analysis, resulted in an
ICER of £15,681 per QALY for EVAR versus OSR. The average
QALY gain at 30 years post surgery was 0.072 for EVAR com-
pared with OSR. Results were most sensitive to the relative risk
of short-term mortality, cost of the EVAR device and long-term
rate of secondary interventions in the EVAR group. CONCLU-
SIONS: The results suggest that EVAR is cost-effective for non-
ruptured AAA versus OSR with a probability of 66% and 60%
based on willingness-to-pay thresholds of £30,000 and £20,000,
respectively.
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OBJECTIVES: To determine if clopidogrel plus aspirin is cost-
effective compared to aspirin alone for patients following ACS,
from the Australian health care perspective. METHODS: A
Markov model was constructed by extrapolation of data from
the Australian Acute Coronary Syndromes Prospective Audit
(ACACIA) registry (n = 2553) in the ﬁrst model cycle, and
the Reduction in Atherothrombosis for Continued Health
(REACH) registry (n = 2567 Australian patients) in subsequent
cycles. Decision analysis was applied to compare clopidogrel
plus aspirin against aspirin alone. Efﬁcacy data were drawn
from the Clopidogrel in Unstable Angina to Prevent Recurrent
Events (CURE) trial. A utility study was conducted in 2007
with 86 participants using health states validated by clinical
experts. Drug and disease costs were obtained from literature
and health care reimbursement fees, and updated using Austra-
lian health price indices. An annual discount rate of 5% was
applied to all costs and effects beyond one year in accordance
with reimbursement guidelines. Twenty sensitivity analyses were
undertaken, varying the 95% conﬁdence intervals surrounding
efﬁcacy measures from CURE, uncertainty in cost and utility
inputs and variations to time horizons and discount rates.
RESULTS: The base-case incremental cost-effectiveness ratio
(ICER) with a ten-year time horizon was A$14,496/QALY and
remained below the unofﬁcial cost-effective threshold of
$A40,000/QALY throughout all sensitivity analyses. Treatment
remained cost-effective up to an inﬂated clopidogrel cost of
229%, and even when acute hospitalization costs were removed
(A$20,267/QALY). The ﬁve-year ICER was A$20,124/QALY.
Sensitivity analyses demonstrated that the ICER ranged from
A$6443/QALY when the risk of events observed in ACACIA
were applied to all years, up to A$36,974/QALY using the 95%
upper conﬁdence interval for efﬁcacy. CONCLUSIONS: Clopi-
dogrel with aspirin represents a highly cost-effective treatment
option for patients with ACS in Australia. This was conﬁrmed
by the Australian reimbursement authority’s recent recommen-
dation that treatment with clopidogrel plus aspirin be reim-
bursed for ACS patients.
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OBJECTIVES: Atrial ﬁbrillation is the most common arrhythmia
in the clinical practice. It is related with an important morbidity,
a decrease in patients’ quality of life and is a risk factor of
suffering a stroke. The Spanish estimated atrial ﬁbrillation preva-
lence is 2.52%, and is higher over 60 years. Radiofrequency
surgical ablation is a treatment alternative to restore sinus
rhythm in drug-refractory atrial ﬁbrillation patients. The main
objective of this study is to develop a ﬁve-year cost-utility analy-
sis including the different treatment alternatives in drug-
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting. METHODS: A Markov model was developed to simu-
late the evolution of a 1000 cohort of over 40 years old patients
with paroxistical and persistent atrial ﬁbrillation that could be
treated with: non ablation, surgical ablation and catheter abla-
tion. The model included four heath states: sinus rhythm, atrial
ﬁbrillation, dependent stroke and death. The time horizon was
ﬁve years, with a cycle length of three months. The data of cost
and effects were obtained from the published literature and
experts opinion. Costs and effects were discounted at 3.5%. A
sensibility analysis was developed to determine the robustness of
the main variables of the model. RESULTS: Based on 1000
patients simulation with concomitant atrial ﬁbrillation, prelimi-
nary results show that the QALY gained were 3.79, 4.25, and
4.23, respectively for no ablation, surgical ablation and catheter
ablation. The costs per patient were respectively 8889, 11,157
and 11,865. The cost per QALY gained of the most effectiveness
option (surgical ablation) when compared with no ablation is
€4909. Surgical ablation is a dominant option vs. catheter abla-
tion. CONCLUSIONS: These preliminary results show that
surgical ablation is a cost-effective treatment option in drug
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting, with less cost and a higher efﬁcacy than the catheter
ablation.
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OBJECTIVES: CUA of the use of valsartan when added to
standard treatment in CHF management in Italy. METHODS: A
probabilistic Markov model, made up of states corresponding to
NYHA classes II, III, IV, and death, was developed in WinBUGS
to apply ﬁndings from the Val-HeFT Trial to the Italian setting.
Simulation lasts 10 years, divided in 1-month cycles. Transition
probabilities represent individual mortality, derived from the
general population mortality by gender and age multiplied by a
NYHA state-speciﬁc HR, and probability of changing NYHA
class, derived from Val-HeFT. The model is informed with
NYHA state- and age-speciﬁc utilities and hospitalization prob-
abilities (adjusted for gender and ACEi-use). Costs are calculated
in the perspective of the Italian NHS and account for drugs and
CHF hospitalizations. The cohort was deﬁned to represent
Italian patients with mild-to-severe CHF and LFEV < 40% over
45 years (Val-HeFT inclusion criteria). Results were calculated
through 30,000 iterations of the patient-level simulation (each
individual is created by drawing from age, gender and ACE-I use
distributions of the cohort). Annual discount rate of 3.5% was
applied to costs and health outcomes. Uncertainty around model
parameters was handled by probabilistic sensitivity analysis
(PSA), performed by simultaneous drawing of each model
parameter from the original data source 95% CI, or from the +/-
10% range where original CI was unavailable. RESULTS: On
average, in the simulation timeframe patients live 4.4 years (3.2
QALYs), with a slight increase in the valsartan group, in which
costs are reduced by approximately €500/pt. In subgroup
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analyses, dominance was lost in ACEi-using and NYHA class II
patients; in these subgroups, the mean ICUR is €17,000–27,000/
QALY. CONCLUSIONS: Valsartan is expected to be cost/
effective for the treatment of Italian patients with mild-to-severe
CHF, and can result cost-saving in selected patients, as compared
to current standard care.
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OBJECTIVES: To determine the cost-effectiveness of endovascu-
lar aneurysm repair (EVAR) versus open surgical repair (OSR)
for acute (ruptured or symptomatic intact), infrarenal abdominal
aortic aneurysm (AAA) in an emergency setting. METHODS: A
two-stage cost-utility model was developed for the recent
appraisal of EVAR by the National Institute for Health and
Clinical Excellence in England and Wales to capture the lifetime
costs and beneﬁts of EVAR for non-ruptured AAA. This model
was adapted to capture the costs and health outcomes of EVAR
for acute AAA. The model population represented a 70-year-old,
ﬁt for open surgery, with an acute AAA. A decision-tree model
captured the short-term costs and health outcomes of patients
during the ﬁrst 30 days post repair, followed by a Markov model,
with monthly cycles during the ﬁrst 24 months and yearly cycles
thereafter, until death. Clinical endpoints included mortality,
complications and secondary interventions. Primary data sources
included a meta-analysis of 23 studies and the EVAR I ran-
domised controlled trial. Costs were applied from trial data and
national reference sources. A discount rate of 3.5% was applied
to costs and health outcomes. Univariate and multivariate sensi-
tivity analyses were performed for all parameters. An incremen-
tal cost-effectiveness ratio (ICER) reﬂecting incremental lifetime
costs per quality-adjusted life-year (QALY) gained was calculated
for the base-case analysis. RESULTS: EVAR dominates OSR in
the base case analysis. The average QALY gain at 30 years post
surgery was 0.064 for EVAR compared with OSR. The results
were not sensitive to changes in parameters. CONCLUSIONS:
The results suggest that EVAR for acute AAA is cost-effective
versus OSR with probabilities approaching 100% based on
willingness-to-pay thresholds of £20,000 and £30,000.
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OBJECTIVES: To evaluate the cost-effectiveness of Dabigatran
(DBG) compared to low-molecular-weight heparin (LMWH), for
the prevention of venous thromboembolism (VTE) following
total hip or knee replacement surgery (THR/TKR) from the
perspective of the UK NHS. METHODS: DBG (220 mg once
daily) was compared to LMWH in patients undergoing THR
(prophylaxis duration 28–35 days) and TKR (6–10 days). The
10-week post-surgery acute phase was modeled via a decision
tree. A Markov process (1 year cycle length) modelled long-term
events (recurrent VTE, post-thrombotic syndrome [PTS] and
consequences of intracranial haemorrhage) for patient’s remain-
ing lifetimes. Relative risks for VTE and bleed events were
derived from the DBG phase III studies, RE-NOVATE and
RE-MODEL which compared DBG with enoxaparin 40 mg once
daily. Probabilities of long-term events were estimated from pub-
lished longitudinal studies. Drug costs (for LMWH a weighted
average was used), resource use associated with administration
of prophylaxis and the management of clinical events, as well as
utility weights, were taken from national sources and published
literature. RESULTS: Thromboprophylaxis with DBG was less
costly than LMWH in TKR and substantially less in THR, since
no nursing time is required either in hospital or following dis-
charge for treatment administration. VTE and bleeding rates
were similar for DBG and LMWH (all differences non-
signiﬁcant). The probabilistic analysis estimated that DBG saved
£93 and £17 per patient on average in THR and TKR respec-
tively; the probability of cost-effectiveness was 99% in THR and
81% in TKR at a willingness to pay threshold of £20,000 per
QALY. Results were shown to be robust across a range of further
sensitivity analyses. CONCLUSIONS: DBG is cost-saving com-
pared to LMWH and non-inferior in terms of efﬁcacy and safety
to enoxaparin 40 mg once daily. Therefore DBG can conﬁdently
be regarded as cost-effective for the prevention of VTE in patients
undergoing THR or TKR.
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OBJECTIVES: An increasing number of studies is demonstrating
that postprandial blood glucose peaks (PPG), which are not
necessarily reﬂected by higher HbA1c values, represent a strong
risk factor for the development of cardiovascular complications.
This study aims to assess the economic effects of an improved
glycemic control by self-monitoring of blood glucose (SMBG)
with respect to coronary artery disease (CAD). METHODS: We
used a Markov model based on the UKPDS risk engine, compar-
ing two type 2 diabetic cohorts (100% male, age 57 years, BMI
29.0, systolic blood pressure 140 mmHg, total cholesterol
5.98 mmol/l, HDL 1.27 mmol/l, baseline HbA1c 8.0%), whereas
one cohort performed (SMBG) and the other not. In a ﬁrst
scenario, we assumed a HbA1c improvement of 0.6% in the
SMBG group compared to the control group. In a second
scenario, an additional reduction of PPG from 10 mmol/l to
7.8 mmol/l was assumed in the SMBG group. RESULTS: In
scenario 1 the mean life expectancy was 8.35 years (SMBG) vs.
8.33 years (No-SMBG), total cost was €15,793 (SMBG) and
€11,217 (No-SMBG). In scenario 2 the mean life expectancy was
8.19 years and 8.01 years (SMBG / No-SMBG group, respec-
tively). The cost effectiveness ratio (ICER) of using SMBG was
€228,800 per life year gained (LYG) in scenario 1 and €20,083/
LYG (scenario 2). CONCLUSIONS: Using only HbA1c as risk
factor for CAD leads to an underestimation of the potential
beneﬁts of SMBG compared to the combination of HbA1c and
PPG. This may lead to a restricted use or even to the exclusion of
a worthwhile health technology. The present assessment is
focused only on CAD and represents a conservative approach.
Further, it has to be examined whether PPG shows similar effects
in other diabetes related complications.
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